This is the second study to demonstrate the ability of the DecisionDx-SCC test to identify patients who are more or less likely to benefit from adjuvant radiation therapy (ART), confirmed in an ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results